Phase 2 Readout~quarter
Phase 2 Readout: bge-102
- Company
- BioAge Labs, Inc. (BIOA)
- Drug
- bge-102
- Indication
- obesity and cardiovascular risk factors
Other upcoming events for BIOA
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.